May: Multiple Sclerosis Awareness Month -- Latest Research Is Good News Medical News Today Thu, 03 May 2007 3:04 AM PDT May is Multiple Sclerosis Month and there is no better way of raising awareness for this unpredictable and often debilitating disease then by highlighting the latest research that might offer hope for the 55 to 75, 000 sufferers across Canada. [click link for full article]

Acorda Therapeutics Presents Data From Its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy ... RedNova Wed, 02 May 2007 6:02 PM PDT Acorda Therapeutics, Inc.? (Nasdaq: ACOR) today presented data from a Phase 3 clinical trial of Fampridine-SR in people with multiple sclerosis (MS) at the American Academy of Neurology meeting.

Rituximab reduces disease activity in multiple sclerosis News-Medical-Net Wed, 02 May 2007 5:49 PM PDT A new drug under investigation shows a reduction in disease activity in multiple sclerosis (MS), according to two studies that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston. The drug reduced disease activity as indicated by MRI scans.

Genzyme And Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab In Multiple Sclerosis Data Presented At AAN Medical News Today Thu, 03 May 2007 0:05 AM PDT Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceutical today announced detailed interim results from the CAMMS223 Phase 2 study. [click link for full article]

No new brain infection cases with Biogen's Tysabri Reuters via Yahoo! News Thu, 03 May 2007 6:13 AM PDT Biogen Idec Inc. said on Thursday that there have been no new confirmed cases of a potentially fatal brain infection associated with its multiple sclerosis drug Tysabri.

Study: New MS drug appears safe, effective New Kerala Thu, 03 May 2007 10:40 AM PDT MONTREAL, May 3: Canadian scientists say a new multiple sclerosis drug undergoing trials appears to be safe and effective. Researchers at the Montreal Neurological Institute said their ongoing investigation is also providing deeper insight into the biology of the complex neurological disease.

Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex Business Wire via Yahoo! Finance Thu, 03 May 2007 8:30 AM PDT CAMBRIDGE, Mass.----Xanthus Pharmaceuticals, Inc today presented data demonstrating that Symadex reversed the clinical and pathological signs of chronic disease in an animal model for multiple sclerosis.

Betaferon reduces disability related to MS: Bayer Schering PharmaBiz Wed, 02 May 2007 11:49 PM PDT Bayer Schering Pharma AG, Germany, has announced new data, which show that immediate initiation of Betaferon (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) can significantly reduce the risk of permanent neurological impairment as measured by the Expanded Disability Status Scale (EDSS) by 40 per cent over three years compared to delayed ...

True country grit
Long Beach Press-Telegram Wed, 02 May 2007 8:31 PM PDT
More than a decade after he was diagnosed with multiple sclerosis, Clay Walker's voice sounds stronger than ever on his first new studio album in four years.